| 2024-10 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study |
Oncologist. 2024 Oct 3;29(10):e1396-e1405. |
 |
| 2024-09-30 |
Registry of genetic alterations of Taiwan non-small cell lung cancer by comprehensive next-generation sequencing: A real-world cohort study-Taiwan cooperative oncology group T1521 |
JCO Global Oncology. 2024 Sep 30;10:Article number e2400125. |
|
| 2024-08-28 |
A statistical method for protocol modifications with heterogeneous population variances |
Statistics in Biopharmaceutical Research. 2024 Aug 28;Article in Press. |
|
| 2024-08-21 |
Immune killer cells treatment for previously treated stage IV NSCLC patients |
Scientific Reports. 2024 Aug 21;14:Article number 19374. |
|
| 2024-07-11 |
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study |
BMC Cancer. 2024 Jul 11;24:Article number 828. |
|
| 2024-06-24 |
The clinical characteristics and manifestation of anxious depression among patients with major depressive disorders-results from a Taiwan multicenter study |
Psychiatry Investigation. 2024 Jun 24;21(6):561-572. |
|
| 2023-11-13 |
Polygenic risk score, environmental tobacco smoke, and risk of lung adenocarcinoma in never-smoking women in Taiwan |
JAMA Network Open. 2023 Nov 13;6(11):Article number e2339254. |
|
| 2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome |
Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390. |
|
| 2023-11 |
The registry of genetic alterations of Taiwan NSCLC by comprehensive next-generation sequencing: A real-world cohort study - TCOG T1521 study |
Journal of Thoracic Oncology. 2023 Nov;18(11, Suppl.):S52. |
|
| 2023-05-26 |
Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population |
Nature Communications. 2023 May 26;14:Article number 3043. |
|
| 2023-05 |
Bayesian hierarchical models for adaptive basket trial designs |
Pharmaceutical Statistics. 2023 May-Jun;22(3):531-546. |
|
| 2022-12 |
Recalibrating risk prediction models by synthesizing data sources: Adapting the lung cancer PLCO model for Taiwan |
Cancer Epidemiology, Biomarkers and Prevention. 2022 Dec 5;31(12):2208-2218. |
|
| 2022-11 |
BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma |
Annals of Oncology. 2022 Nov;33(Suppl. 9):S1472-S1473. |
|
| 2022-10 |
Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study |
Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257. |
|
| 2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S478. |
|
| 2022-06-02 |
Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma |
Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536. |
|
| 2022-06 |
Three-stage pooled plasma hepatitis C virus RNA testing for the identification of acute HCV infections in at-risk populations |
Microbiology Spectrum. 2022 Jun 29;10(3):Article number e0243721. |
|
| 2022-01 |
Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances |
Statistics in Medicine. 2022 Jan 15;41(1):87-107. |
|
| 2022-01 |
Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients |
Clinical and Translational Radiation Oncology. 2022 Jan;32:59-68. |
|
| 2021-11-12 |
The prognostic and predictive role of chromogranin a in gastroenteropancreatic neuroendocrine tumors - A single-center experience |
Frontiers in Oncology. 2021 Nov 12;11:Article number 741096. |
|
| 2021-09-27 |
Comment on"Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment": Is real-world evidence real? |
Statistics in Biopharmaceutical Research. 2021 Sep 27;15(1):18-19. |
|
| 2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2021 Sep;32(Suppl. 5):S377. |
|
| 2021-05 |
High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial |
Radiotherapy and Oncology. 2021 May;158:146-154. |
|
| 2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143. |
|
| 2021-05 |
A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025. |
|
| 2021-02-05 |
Tolerance interval testing for assessing accuracy and precision simultaneously |
PLoS ONE. 2021 Feb 5;16(2):Article number e0246642. |
|
| 2021-02 |
On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes |
Contemporary Clinical Trials. 20201 Feb;101:Article number 106244. |
|
| 2021-01 |
Use of a two-sided tolerance interval in the design and evaluation of biosimilarity in clinical studies |
Pharmaceutical Statistics. 2021 Jan;20(1):175-184. |
|
| 2020-12-29 |
Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia |
Environment International. 2020 Dec 29;147:Article number 105975. |
|
| 2020-12-02 |
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) |
PLoS ONE. 2020 Dec 2;15(12):Article number e0242763. |
|
| 2020-11 |
Use of tolerance intervals for assessing biosimilarity |
Statistics in Medicine. 2020 Nov;39(26):3806-3822. |
|
| 2020-10 |
Operational experiences in China and statistical issues on the conduct of clinical trials during the COVID-19 pandemic |
Statistics in Biopharmaceutical Research. 2020 Oct;12(4):438-442. |
|
| 2020-09-02 |
Use of a tolerance interval approach as a statistical quality control tool for traditional Chinese medicine |
Journal of Biopharmaceutical Statistics. 2020 Spe 2;30(5):873-881. |
|
| 2020-07-01 |
A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue |
Haematologica. 2020 Jul 1;105(7):e349-e354. |
|
| 2020-05 |
An open-label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy of TLC388 and genomic analysis for poorly differentiated neuroendocrine carcinomas |
Oncologist. 2020 May;25(5):e782-e788. |
|
| 2020-04-21 |
Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women |
Scientific Reports. 2020 Apr 21;10:Article number 6774. |
|
| 2020-03 |
Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women |
Genomics. 2020 Mar;112(2):1223-1232. |
|
| 2020-02 |
Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model |
Cancer Epidemiology, Biomarkers and Prevention. 2020 Feb;29(2):452-459. |
|
| 2020-01 |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection |
Journal of the Formosan Medical Association = Taiwan Yi Zhi. 2020 Jan;119(1):335-344. |
|
| 2020-01 |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study |
European Journal of Cancer. 2020 Jan;124:123-130. |
|
| 2019-07 |
Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes |
Statistical Methods in Medical Research. 2019 Jul;28(7):2179-2195. |
|
| 2019-05 |
An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14) |
Journal of Clinical Oncology. 2019 May;37(15, Suppl. S):Abstract number 4101. |
|
| 2018-09 |
Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study |
Annals of Oncology. 2018 Sep;29(9):1972-1979. |
|
| 2018-08-21 |
Design and data analysis of multiregional clinical trials (MRCTs)—Theory and practice |
Biopharmaceutical Applied Statistics Symposium : Design of Clinical Trials. 2018 Aug 21;Chapter 10:269-286. |
|
| 2018-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients |
Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598. |
|
| 2018-01 |
Use of a Bayesian approach in the design and evaluation of NCE2s |
Journal of Food and Drug Analysis. 2018 Jan;26(1):416-421. |
|
| 2017-11-23 |
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy |
Scientific Reports. 2017 Nov 23;7:Article number 16187. |
|
| 2017-11 |
Intake of potassium- and magnesium-enriched salt improves functional outcome after stroke: A randomized, multicenter, double-blind controlled trial |
American Journal of Clinical Nutrition. 2017 Nov;106(5):1267-1273. |
|
| 2017-10 |
Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma |
Asia Pacific Journal of Clinical Nutrition. 2017 Oct;13(5):E304-E311. |
|
| 2017-09 |
A tolerance interval approach to assessing the biosimilarity of follow-on biologics |
Statistics in Biopharmaceutical Research. 2017 Sep;9(3):286-292. |
|
orcid.org/0000-0003-1284-7260
